Lupin Partners with Galenicum Health for Injectable Semaglutide Distribution

Lupin's subsidiary, Lupin Atlantis Holdings SA, has signed a licensing and supply agreement with Galenicum Health for injectable Semaglutide, a GLP-1 receptor agonist used in managing Type 2 Diabetes and obesity. Under the deal, Galenicum will handle development, manufacturing, and supply, while Lupin will manage regulatory approvals, commercialization, and distribution across 23 countries including Canada, Europe, Southeast Asia, and Latin America. The partnership aims to expand Lupin's presence in the global diabetes and obesity treatment markets.